PET amyloid-beta imaging in preclinical Alzheimer's disease.
PET amyloid-beta imaging in preclinical Alzheimer's disease.
复制标题
DOI：
10.1016/j.bbadis.2011.11.005
复制
发表时间：
2012-03
影响因子：
6.2
通讯作者：
Morris, John C.
中科院分区：
文献类型：
--
作者：
Vlassenko, Andrei G.;Benzinger, Tammie L. S.;Morris, John C.
阿尔茨海默病（AD）是痴呆的主要原因，占所有病例的60-70%[Hebert et al.，2003，1]。对AD的有效治疗的需求是巨大的。目前的方法，包括胆碱酯酶抑制剂和N-甲基-d-天冬氨酸（NMDA）受体拮抗剂，是AD的对症治疗，但不能阻止疾病进展。许多AD的诊断和治疗方法目前正在改变，这是由于认识到潜在的病理学在痴呆的临床体征出现之前10至20年就开始了[Holtzman等人，2011，2]。需要新的治疗方法，重点是预防或延迟发作或认知症状。在识别AD生物标志物方面的最新进展现在使得在认知正常（CN）个体中检测疾病的临床前阶段的AD病理成为可能;该生物标志物数据应用于选择用于临床试验的高风险人群。AD神经病理学的体内可视化和治疗效果的生物学、生物化学或生理学确认可能会大大改善新型药物的开发。正电子发射断层扫描（PET）是领先的神经影像学工具，可在早期阶段检测和提供体内AD淀粉样病变的定量测量，并纵向跟踪其病程。这篇文章是特刊的一部分，题为：成像脑老化和神经退行性疾病。
Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all cases [Hebert et al., 2003, 1]. The need for effective therapies for AD is great. Current approaches, including cholinesterase inhibitors and N-methyl-d-aspartate (NMDA) receptor antagonists, are symptomatic treatments for AD but do not prevent disease progression. Many diagnostic and therapeutic approaches to AD are currently changing due to the knowledge that underlying pathology starts 10 to 20years before clinical signs of dementia appear [Holtzman et al., 2011, 2]. New therapies which focus on prevention or delay of the onset or cognitive symptoms are needed. Recent advances in the identification of AD biomarkers now make it possible to detect AD pathology in the preclinical stage of the disease, in cognitively normal (CN) individuals; this biomarker data should be used in the selection of high-risk populations for clinical trials. In vivo visualization of AD neuropathology and biological, biochemical or physiological confirmation of the effects of treatment likely will substantially improve development of novel pharmaceuticals. Positron emission tomography (PET) is the leading neuroimaging tool to detect and provide quantitative measures of AD amyloid pathology in vivo at the early stages and follow its course longitudinally. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.
登录
查看更多内容
影响因子：
3.7
作者：
Dickerson, Bradford C.;Bakkour, Akram;Salat, David H.;Feczko, Eric;Pacheco, Jenni;Greve, Douglas N.;Grodstein, Fran;Wright, Christopher I.;Blacker, Deborah;Rosas, H. Diana;Sperling, Reisa A.;Atri, Alireza;Growdon, John H.;Hyman, Bradley T.;Morris, John C.;Fischl, Bruce;Buckner, Randy L.
通讯作者：
Buckner, Randy L.
影响因子：
5.3
作者：
Adlard, PA;Perreau, VM;Cotman, CW
通讯作者：
Cotman, CW
影响因子：
6.1
作者：
Fagan, AM;Watson, M;Holtzman, DM
通讯作者：
Holtzman, DM
影响因子：
15.9
作者：
Ewers M;Sperling RA;Klunk WE;Weiner MW;Hampel H
通讯作者：
Hampel H
DOI：
10.1001/jama.2010.2008
发表时间：
2011-01-19
期刊：
JAMA
影响因子：
--
作者：
Clark CM;Schneider JA;Bedell BJ;Beach TG;Bilker WB;Mintun MA;Pontecorvo MJ;Hefti F;Carpenter AP;Flitter ML;Krautkramer MJ;Kung HF;Coleman RE;Doraiswamy PM;Fleisher AS;Sabbagh MN;Sadowsky CH;Reiman EP;Zehntner SP;Skovronsky DM;AV45-A07 Study Group
通讯作者：
AV45-A07 Study Group